This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc Health (TDOC) Q3 Loss Narrows on Integrated Care Strength
by Zacks Equity Research
Teladoc Health's (TDOC) Q3 results were aided by membership growth in the Integrated Care unit as well as strong BetterHelp revenues. Management presently expects 2023 net loss per share to be within $1.50-$1.40.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Analyst Blog Highlights Toyota Motor, Elevance Health, Illinois Tool Works, Ross Stores and Yum China
by Zacks Equity Research
Toyota Motor, Elevance Health, Illinois Tool Works, Ross Stores and Yum China are part of the Zacks top Analyst Blog.
Top Analyst Reports for Toyota Motor, Elevance Health & Illinois Tool Works
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Toyota Motor Corporation (TM), Elevance Health, Inc. (ELV) and Illinois Tool Works Inc. (ITW).
Is Elevance Health (ELV) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Elevance Health (ELV) could produce exceptional returns because of its solid growth attributes.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Elevance Health (ELV) Q3 Earnings Beat on Carelon Unit Strength
by Zacks Equity Research
Membership growth in the Medicare Advantage business and strong segmental performance aid Elevance Health's (ELV) Q3 results. An encouraging 2023 earnings guidance also bodes well for investors.
Elevance Health (ELV) Beats Q3 Earnings, Hikes '23 Profit View
by Zacks Equity Research
Elevance Health's (ELV) Q3 results gain on growing medical customer base and strong pharmacy product revenues. Adjusted net income is currently projected to be more than $33.00 per share for 2023.
Here's What Key Metrics Tell Us About Elevance Health (ELV) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Elevance Health (ELV) Q3 Earnings Top Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 6.39% and 0.12%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Badger Meter (BMI) to Post Q3 Earnings: Key Factors to Note
by Zacks Equity Research
Badger Meter's (BMI) third-quarter performance is likely to have benefited from increased demand for its digital smart water solutions.
Factors to Note Ahead of Iridium's (IRDM) Q3 Earnings Release
by Zacks Equity Research
Iridium's (IRDM) third-quarter performance is likely to have benefited from momentum in the Service, and Engineering and Support Service segments.
Is a Surprise Coming for Elevance Health (ELV) This Earnings Season?
by Zacks Equity Research
Elevance Health (ELV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SAP Set to Report Q3 Earnings: Here's What You Should Know
by Zacks Equity Research
SAP's third-quarter performance is likely to have benefited from continued momentum in cloud business. However, prevailing global macroeconomic challenges may have acted as a dampener.
(ELV) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, Elevance Health (ELV) closed at $454.11, indicating a +0.13% shift from the previous trading day.
Can Elevance's (ELV) Q3 Earnings Beat on Carelon Strength?
by Zacks Equity Research
The third-quarter results of Elevance (ELV) are likely to reflect strong rate adjustments and membership growth in the Health Benefits business.
Elevance Health (ELV) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Elevance Health (ELV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ELV vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ELV vs. HQY: Which Stock Is the Better Value Option?
Elevance Health (ELV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Elevance Health (ELV) Could Beat Earnings Estimates Again
by Zacks Equity Research
Elevance Health (ELV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Elevance Health (ELV) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cigna (CI) Unveils 2024 Expansion Plans, Eyes Membership Growth
by Zacks Equity Research
Cigna (CI) declares the availability of a varied set of health plans across new counties in 2024. It, thereby, places intensified focus on growing its Medicare business.
Elevance Health (ELV) to Expand in 91 New Counties in 2024
by Zacks Equity Research
Elevance Health (ELV) is set to enhance its product suite and expand to 91 counties in 2024, improving the overall health of people.
Elevance Health (ELV) Hits Pause on $2.5B BCBSLA Acquisition
by Zacks Equity Research
Elevance Health (ELV) and BCBS Louisiana have opted to withdraw the acquisition application from the Louisiana Department of Insurance.